Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
about
Responses of Pseudomonas aeruginosa to antimicrobialsEsrC, an envelope stress-regulated repressor of the mexCD-oprJ multidrug efflux operon in Pseudomonas aeruginosaDynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations.Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators.Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosaPseudomonas aeruginosa: resistance to the maxMass Spectrometry Analysis of Pseudomonas aeruginosa Treated with Azithromycin.Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of CiprofloxacinNosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.Cystic fibrosis - a multiorgan protein misfolding disease.Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.The problems of antibiotic resistance in cystic fibrosis and solutions.Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.Increased IL-8 production in human bronchial epithelial cells after exposure to azithromycin-pretreated Pseudomonas aeruginosa in vitro.Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.Surfactant protein A blocks recognition of Pseudomonas aeruginosa by CKAP4/P63 on airway epithelial cells.Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance MechanismsThe Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to β-lactams, fitness, biofilm growth, and global regulation.Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study.Mutational Evolution of Resistance to Ribosome-Targeting Antibiotics
P2860
Q28305587-F5611E06-9ED0-4CE0-B177-6C370FC3A0A6Q28492825-8122689D-50C1-4F3E-9BCE-65C3BFCB9003Q31029779-DCDEE186-3FAD-462D-BA90-FB0743D73606Q31138535-D2D31D7C-2FC5-44F0-A3E0-26CCF7E3ACF0Q34082906-D0BE10C1-30D2-4577-94F0-649158C20F0AQ34932869-997907F7-E8FB-4DE4-8F8B-9F814A828623Q35065762-188DC751-B096-4773-9EAD-3F2A9515079AQ35084559-622CB728-685A-4299-A915-DCFC2B540096Q35584832-8B3C77C0-E564-4891-B2C1-DD6C5A1AC657Q35939649-44D5FDB9-E655-4F46-8698-315C57485E3BQ36228925-75084B1D-E19C-4E2F-9659-F29B75F45EA1Q37302114-A9918515-9AFE-44E0-81D1-ABB489CD4902Q37474478-5B835040-2E48-402D-A15E-9898C5785C64Q38049220-786C4064-7A23-4DFC-BB4D-E27C287ECFB0Q38300820-E3FD5657-49AD-49DE-A28A-CAA3684300ACQ38529613-8898B557-F455-40D4-AB6F-155A92BA9533Q38626934-1C7B5358-BAD4-498E-A41E-3D6370F974BBQ38938501-97DB2B48-70EC-4F56-82CE-360E793F97B8Q39005987-86DB5A6E-4A3A-40F8-8CD0-DC378F8247BAQ39172960-BC3F8234-F8DC-4980-906F-12B34DBCAF14Q39281402-4C24F76B-A966-4486-AEC8-5CCF25938868Q39683346-A42DC0F4-24C7-4EDA-ADDA-3D05417A093CQ40592595-02CC55F9-09DD-4A9B-9B5A-9A430D1C8657Q41834172-94A6E512-34FD-422D-98B7-5EF9F28840BAQ42421195-6A408DB2-9D85-4065-B8C2-DD60F333990AQ46958203-86B54E7E-14A1-4E5A-9B14-8A20E61166D9Q58596095-23714553-3F07-41F5-A870-26D3F14AFBB8
P2860
Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@en
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@nl
type
label
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@en
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@nl
prefLabel
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@en
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@nl
P2093
P2860
P356
P1476
Azithromycin in Pseudomonas ae ...... and selection of nfxB mutants.
@en
P2093
Antonio Oliver
José L Pérez
María D Maciá
Xavier Mulet
P2860
P304
P356
10.1128/AAC.01264-08
P407
P50
P577
2009-02-02T00:00:00Z